Kornimate/medical-research-clean huggingface dataset:
investigation of a digital healthy habits program for individuals with breast cancer

Conditions: Cancer; Breast Cancer; Obesity; Overweight and Obesity; Overweight

Summary: this mixed methods study will involve obtaining user feedback on the first 4 weeks of the healthy habits for cancer (hcc) program. short pre and post surveys and in-depth qualitative interviews will be conducted exploring their views on the app (features they liked and didn't like), the extent to which they believe the app would have to be further adapted, how they would feel about such an app being embedded in their cancer care and when in their care pathway they would like to be offered it.

this mixed methods study will involve obtaining user feedback on the first 4 weeks of the healthy habits for cancer (hcc) program. participants will be recruited and asked to try the hcc app for 4 weeks. short pre and post surveys and in-depth qualitative interviews will be conducted exploring their views on the app, the extent to which they believe the app would have to be further adapted, how they would feel about such an app being embedded in their cancer care and when in their care pathway they would like to be offered it.

Eligibility criteria:
inclusion criteria: * able to understand and provide informed consent * 18 years and older * female * \> 6 months postpartum * not currently pregnant or planning to become pregnant in the next 5 months * diagnosed with stage i-iv breast cancer \< 5 years ago: * completed active breast cancer treatment (e.g., chemotherapy, radiation, surgery) 1 month to 5 years ago, with the exception of hormonal/endocrine therapy * currently prescribed hormone therapy (e.g. tamoxifen) as a breast cancer treatment * not diagnosed with an eating disorder * healthy weight, overweight, or obesity (bmi ≥ 18.5) * willingness to use the program over the course of the 4 weeks in order to enable them to provide feedback on its features * own a smartphone with ios operating system (i.e., apple iphone) exclusion criteria: * inability or unwillingness of a participant to give written informed consent * underweight (bmi \< 18.5) * currently pregnant or \<6 months postpartum * presence of a diagnosed physical or mental health condition or abnormality that impacts the ability to participate in a program that involves asking participants to monitor diet, physical activity, or weight (e.g., eating disorder, bipolar disorder). if there is any doubt at initial screening the investigator will recommend that the patient receives sign off from their clinical team. * currently undergoing iv chemotherapy or radiation * plans for surgery in the next 6 weeks * currently diagnosed or being treated for a second primary cancer (i.e. cancer of another organ, not due to breast cancer metastasis), with the exception of non-melanoma skin cancers (e.g. basal cell carcinoma)
phase i clinical safety study about human umbilical cord blood monocyte in the acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the objective of the study is to determine the safely of human umbilical cord blood mononuclear cells by intravenous injection in acute ischemic stroke patients.

the study will use umbilical cord blood cells (a special kind of cell that is believed to be a stem cell) isolated from ucb (blood obtained at birth from the umbilical cord blood of babies). stemcyte, a leading accredited ucb banking company with branches in the united states and taiwan, will provide the units of ucb that match at least 4 out of 6 hla (human leukocyte antigens) for transplantation. the hla-matching is the same as that used to match cells and organs for transplantation so that the body does not reject the cells. then cells injection by intravenous in acute ischemic stroke patients.

Eligibility criteria:
inclusion criteria: 1. the age of subjects between 45 through 80 years. 2. acute ischemic stroke. 3. national institutes of health stroke scale (nihss):6-18 4. brain mri shows the middle cerebral artery region (m1 and m2) of cerebral i infarction stroke patients. 5. subjects have no midline shift or hemorrhagic transformation exclusion criteria: 1. nihss score reduced more than 4 within after 24 hours. 2. female are pregnant or lactating. 3. subjects with impaired liver function, aids, cancer or other significant medical condition (including certifiable diseases, rare disease) 4. subjects joined other clinical trails or received rt-pa therapy. 5. immune dysfunction or receiving other immunosuppressive agents. 6. subjects cannot have mri test 7. subjects' hla typing results match less than 4 out of the 6 genotypes

Keywords: acute ischemic stroke umbilical cord blood
prognostic molecular markers in patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome

Summary: in the era of hypomethylating agent in mds treatment, the investigators aimed to investigate the prognostic impact of mutations in spliceosome machinery genes (srsf2, u2af1, and zrsr2) on the outcomes of 1st line decitabine treatment in mds.

a number of studies have tried to investigate clinical impact of mutations in spliceosomal machinery genes in mds but they failed to demonstrate a consistent prognostic relevance. moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent treatment in mds has never been explored yet. the investigators investigated the prognostic impact of mutations in spliceosome machinery genes (srsf2, u2af1, and zrsr2) on the outcomes of 1st line decitabine treatment in mds.

Eligibility criteria:
inclusion criteria: * de novo mds patients were included in the study who had received 1st line decitabine treatment and had adequate genomic dna from pretreated bone marrow samples exclusion criteria: * therapy-related mds

Keywords: myelodysplastic syndrome decitabine spliceosome mutation
prediction model of occult omental metastasis in patients with gastric cancer

Conditions: Gastric Cancer; Omental Metastasis

Summary: a complete omentectomy is typically recommended during radical total gastrectomy for gastric cancer, though its impact on survival remains unclear. this study aimed to assess the frequency and risk factors of metastases in the greater omentum in gastric cancer patients undergoing gastrectomy. it will involve a single prospective cohort of consecutive patients who underwent total gastrectomy with complete en bloc omentectomy and modified d2 lymphadenectomy. post-surgery, the omentum will dissect from the gastrectomy specimen beyond the gastroepiploic vessels and examine separately for pathological assessment. the primary outcome will focus on the detection of omental metastases.


Eligibility criteria:
inclusion criteria: 1. pathological confirmation of gastric cancer 2. eligibility for surgical intervention 3. undergoing first rectal cancer surgery 4. acquisition of written informed consent from patients and their families 5. no history of hypertrophic scar or allergic predispositions exclusion criteria: 1. absence of postoperative pathology of the omentum 2. diagnosis of multiple primary malignancies 3. intraoperative discovery of widespread implant metastases within the abdominal cavity 4. severe comorbidities
exploring the predictive value of electroencephalography features in perioperative neurocognitive disorders following cardiovascular surgery

Conditions: Cardiovascular Surgery; Perioperative Neurocognitive Disorders

Summary: to explore the predictive value of electroencephalography features in perioperative neurocognitive disorders in patients undergoing cardiovascular surgery under general anesthesia

data was acquired on the ward using a 10-20 system with a standard 32-channel eeg cap and an eeg instrument (bp company, gilching, germany). patients were tested using cognitive assessment scales before and after surgery. cognitive levels were assessed 1 day before surgery and 1 week after surgery (7±2 days) using the montreal cognitive assessment (moca) . patients were followed up one month (30±2 days) after surgery using the telephone version of the montreal cognitive assessment scale (t-moca). preoperative and postoperative electroencephalography brain network-related indexes (such as cluster coefficient, small world index, etc.) in patients with pnd will be included in the analysis.

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. undergoing coronary artery bypass surgery or valve replacement surgery under general anaesthesia 3. asa grade: ii-iv 4. older than 60 years 5. able to complete cognitive function tests exclusion criteria: 1. history of severe neurological diseases and psychiatric diseases 2. history of drug abuse 3. severe hearing or vision impairment 4. preoperative delirium 5. serious adverse reactions such as cardiac arrest and cardiopulmonary resuscitation during surgery 6. patients undergoing secondary surgery in a short period 7. participation in concurrent clinical trials

Keywords: perioperative neurocognitive disorders;electroencephalography
frequency of patho-morphological classes of gall stones in lahore, pakistan

Conditions: Gallstone

Summary: it is a cross sectional study in which we are tying to determine frequency of type of gall stones in our setup(lahore, pakistan).


Eligibility criteria:
inclusion criteria: 1. patients with any sex age 1 2. 5 years and above 3. presenting to opd with cholelithiasis - exclusion criteria: 1. patients who develop gallstones after bariatric surgery 2. less than 15 years of age
naturally controlled decongestion using renal independent system in adhf patients, a european registry

Conditions: Chronic Heart Failure; Fluid Overload; Acute Decompensated Heart Failure; Edema

Summary: the aquapass is a non-invasive, renal-intended system designed to enhance fluid transfer through the skin, by increasing sweat rate, to treat fluid overload in heart failure patients. this study will further evaluate the safety, efficacy, and usability of the aquapass system in the hospital and home settings.

the aquapass system is non-invasive and functions independently of the renal system, targeting the direct removal of fluids directly from the interstitial compartment through the skin, by activating the eccrine sweat glands. the patient wears a component that is connected to a control unit, which induces warm air to create a controlled environment around the skin, stimulating sweat production. the sweat evaporates instantly, ensuring that the patient remains dry and comfortable. in this study, the investigators would like to further investigate the efficacy of the system, when used in hospital settings in patients hospitalized for decompensated heart failure and fluid overload, and to continue the treatment in their homes, immediately after the hospitalization, for another 30 days.

Eligibility criteria:
inclusion criteria: * subject that was hospitalized with fluid overload and a history of chronic heart failure and ckd stages 1-4 * subject has composite congestion score ≥3. * baseline systolic blood pressure at rest of ≥100mmhg. * subject is capable of meeting the following study requirements: * for patients with bmi \ 1,600 pg/ml * for patients with bmi \>30 kg/m2: baseline nt-pro bnp \>800 pg/ml * for patients with rate-controlled persistent or permanent af: nt-pro bnp \>2,400 pg/ml. * subject successfully completes 2-4 hours of run-in acclimation session * minimal sweat rate in the last hour of run-in acclimatization of 130gr/hours exclusion criteria: * subject is enrolled to another clinical investigation that might interfere with this study. * baseline systolic blood pressure \<100 mm hg * subject considered to be in the acute worsening of the heart failure: requiring ventilation, mechanical support or is clinically unstable requiring pressors, deterioration triggered by arrythmia, infection or other medical condition unrelated to fluid overload. * subject has any known lower body skin problems (open wounds, ulcers) * subject with severe peripheral arterial disease * subject is pregnant or planning to become pregnant within the study period, or lactating mothers. * end-stage renal disease (egfr\<15 ml/min/1.73 m2) or requiring dialysis. * inability or unwillingness to comply with the study requirements. * history of heart transplant or actively listed for heart transplant or left ventricular assist device (lvad). * implanted left ventricular assist device or implant anticipated \<3 months. * malignancy or other noncardiac condition limiting life expectancy to \<12 months.
association between temporomandibular disorders and sleep disorders

Conditions: Temporomandibular Disorders (TMD); Sleep

Summary: association between temporomandibular disorders and sleep disorders

temporomandibular disorders (tmd) are complex conditions, which can have a significant impact on patients' health and quality of life. furthermore, they are unclearly associated with sleep disorders. the aim of the study is to investigate the prevalence of tmd in patients with sleep disorders.

Eligibility criteria:
inclusion criteria: * age \>18 years * famale and male * signature of the privacy information form * signature of the informed consent form of the protocol * subjects capable of understanding and wanting * subjects suffering from a sleep disorder (insomnia,hypersomnia,restless legs syndrome,rem sleep behavior disorder,narcolepsy,obstructive sleep apnea syndrome (osas),primary snoring, rem parasomnias,nocturnal epilepsy) exclusion criteria: * physical trauma to the head and neck area * painful oral pathologies (e.g. pulpitis, tooth fractures, tooth abscesses, tooth decay, canker sores and mucosal wounds) * recent dental treatments that may cause pain (e.g. tooth extraction, tooth root canal) * use of oral contraceptives * subjects not capable of understanding and wanting * patients suffering from neurological pathologies that may interfere with the completion of the questionnaires (es dementia) or psychiatric pathologies or drug use as per dsm-5 criteria (including schizophrenia, bipolar, major depression, substance abuse, personality disorders).
zinc bioavailability from amaranth-enriched maize tortillas

Conditions: Nutritional Deficiency

Summary: young children in guatemala are at risk for nutrient deficiencies due to plant-based diets and poor sanitation. stunting, frequent diarrhea, and respiratory infections are common. supplementation of zn to children during diarrhea episodes has been shown to diminish duration and severity of illness. poor zn absorption due to high fiber and phytate in this diet might play a role in these processes. supplementation of this micronutrient in the diet might be beneficial. the investigators will compare absorption of zn from white maize tortillas enriched with 20% amaranth to traditional white corn tortillas in preschool children in guatemala.

this is a randomized cross-over study of zinc absorption in young children living in the western highlands of guatemala. absorption of zinc will be measured from maize tortillas and maize tortillas fortified with 20% amaranth as the major food staple which provides at least 70% energy and at least 90% zinc and phytate of the diet. participants will be randomized as to which type of tortilla they receive on the first and second day. fractional absorption of zinc (faz) from all meals in one day for one type of tortilla and one day for the other will be measured by extrinsic labeling with stable isotopes of zinc. faz will be measured by a dual isotope tracer ratio (ditr) technique based on ratio of urine enrichment of orally versus intravenously administered zinc stable isotopes. measurement of total zinc in duplicate diets on test days allow for determination of quantities of this micronutrient absorbed.

Eligibility criteria:
inclusion criteria: * 2-3 years of age * apparently healthy * eats \>2-3 tortillas at each meal of the day. exclusion criteria: * chispitas or macrovital supplementation * breastfeeding * birth weight \< 2,500 g * birth defect affecting growth and development * chronic infection * twin or triplet * sibling enrolled in study

Keywords: zinc absorption maize amaranth guatemala stable isotopes of zn
a study of bgb-24714 as monotherapy and with combination therapies in participants with solid tumors

Conditions: Solid Tumor, Adult

Summary: this study aims to understand how safe and well-tolerated a drug called bgb-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. the main objective is to identify the highest tolerable dose or the highest administered dose of bgb-24714. additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.


Eligibility criteria:
key eligibility criteria : 1. participants must sign a written informed consent form (icf); and agree to comply with study requirement 2. phase 1a (dose escalation): part a, a-cn, and b: participants with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumor previously treated with standard systemic therapy or for whom treatment is not available or not tolerated note: only chinese participants will be eligible for part a-cn. part c: participant has histologically or cytologically confirmed, locally advanced, unresectable stage iii non-small cell lung cancer (nsclc) suitable for definitive chemoradiotherapy (crt) part d: participant with locally advanced, histologically confirmed inoperable esophageal squamous cell carcinoma (escc) suitable for definitive crt phase 1b (dose expansion): participants with histologically or cytologically confirmed solid tumors of selected types previously treated with standard therapy. 3. participants must be able to provide formalin-fixed paraffin embedded (ffpe) tumor tissue sample. 4. phase 1a part a, a-cn, b and phase 1b: ≥ 1 measurable lesion per response evaluation criteria in solid tumors (recist) v1.1 5. eastern cooperative oncology group (ecog) performance status ≤ 1 key exclusion criteria: 1. active leptomeningeal disease or uncontrolled, untreated brain metastasis. 2. any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent 3. any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before the first dose of study drug(s). 4. clinically significant infection requiring systemic therapy ≤ 14 days before the first dose of study drug(s). 5. prior exposure to agents with second mitochondria-derived activator of caspases (smac) mimetics, or other inhibitors of apoptosis proteins (iaps) antagonists. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: solid tumors advanced solid tumors metastatic solid tumors
intraoperative direct vs postoperative ultrasound guided adductor canal nerve block after total knee arthroplasty

Conditions: Knee Osteoarthritis; Total Knee Arthroplasty; Nerve Block

Summary: this study compares analgesic effect between two techniques of adductor canal nerve block after total knee arthroplasty. the first group of the patients will receive intraoperative adductor canal nerve block; and the other group post operative ultrasound guided adductor canal nerve block. investigators will measure postoperative opioid consumption, pain management and rehabilitation goals.

total knee arthroplasty (tka) is a successful alternative to treat late stage knee osteoarthritis (oa). pain management has been one of the main focuses of postoperative care. most surgeons prefer a comprehensive multimodal approach including preoperative pharmacological treatment, intraoperative infiltration with complex drug mixes and postoperative peripheral nerve block. the most common postoperative nerve block alternative is the proximal femoral nerve block (fnb) which has shown improvements on postoperative pain measured by reduced opioid consumption and decreased pain at rest. its main detractors argue that the motor nerve block effect is deleterious to early ambulation and have promoted adductor canal nerve blocks (acb). described by lund et al in 2011, acb block main femoral pain sensory contributors to the knee (articular branches of obturator nerve, vastus medialis branch and saphenous nerve) but is more distal to most motor branches to the quadriceps allowing near to normal quadriceps strength. standard acb block is performed under ultrasound guidance after surgery completion, still in the operating room (or). recent literature has shown the anatomic feasibility of intraoperative acb via blunt suprapatellar dissection in standard medial parapatellar tka approaches. the study seeks to determine the effectiveness of standard ultrasound guidance acb compared with intraoperative acb.

Eligibility criteria:
inclusion criteria: * primary total knee arthroplasty * unilateral * american society of anesthesiologists (asa) score i, ii or iii * accepts spinal anesthesia exclusion criteria: * general anesthesia * chronic kidney disease * drug or alcohol abuse * chronic opioid use * allergic to bupivacaine or similar
study evaluating sphenopalatine ganglion block (spgb) for treatment of postdural puncture headache (pdph)

Conditions: Postdural Puncture Headache

Summary: postdural puncture headaches (pdph) are a consequence of spinal and epidural anesthesia in approximately 1% of cases when performed in obstetric patients. the gold standard treatment for a pdph is currently an epidural blood patch (ebp), which involves placing a needle back into the epidural space of the neuraxium and then injecting 20 ml of the patient's own blood through the needle and into the epidural space to form a clot over the insult in the tissue layer that causes the headaches. the investigators want to test the efficacy of using a less invasive procedure, called a sphenopalatine block (spgb), for treatment of pdph. spgb has been used for many years in the treatment of migraines and cluster headaches, and there are several case reports of its use to successfully treat pdph as well. spgb simply involves applying a local anesthetic to the mucosa in the back of each nostril to numb the nerves that cause the headache. the investigators hope that the spgb will reduce the number of pdph patients that require and ebp.


Eligibility criteria:
inclusion criteria * active postdural puncture headache within 7 days after neuraxial analgesia/anesthesia * age ≥ 18 years. * asa physical status ≤ 3 exclusion criteria * known coagulopathy * known nasal septal deviation or abnormalities * medical conditions contraindicated to bupivacaine or the nasal applicator (according to the product labeling)